IL310894A - Milovacian for the prevention and treatment of thromboembolic disorders - Google Patents

Milovacian for the prevention and treatment of thromboembolic disorders

Info

Publication number
IL310894A
IL310894A IL310894A IL31089424A IL310894A IL 310894 A IL310894 A IL 310894A IL 310894 A IL310894 A IL 310894A IL 31089424 A IL31089424 A IL 31089424A IL 310894 A IL310894 A IL 310894A
Authority
IL
Israel
Prior art keywords
daily dose
milvexian
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Application number
IL310894A
Other languages
English (en)
Hebrew (he)
Inventor
John Strony
Gary Peters
Madhu Chintala
Christopher Nessel
Liyanage Vidya Perera
Danshi Li
Joseph M Luettgen
Dietmar Alfred Seiffert
Charlotte Jones-Burton
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
John Strony
Gary Peters
Madhu Chintala
Christopher Nessel
Liyanage Vidya Perera
Danshi Li
Joseph M Luettgen
Dietmar Alfred Seiffert
Jones Burton Charlotte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv, John Strony, Gary Peters, Madhu Chintala, Christopher Nessel, Liyanage Vidya Perera, Danshi Li, Joseph M Luettgen, Dietmar Alfred Seiffert, Jones Burton Charlotte filed Critical Bristol Myers Squibb Co
Publication of IL310894A publication Critical patent/IL310894A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL310894A 2021-09-17 2022-09-16 Milovacian for the prevention and treatment of thromboembolic disorders IL310894A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US202163278582P 2021-11-12 2021-11-12
PCT/US2022/043797 WO2023043999A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Publications (1)

Publication Number Publication Date
IL310894A true IL310894A (en) 2024-04-01

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310894A IL310894A (en) 2021-09-17 2022-09-16 Milovacian for the prevention and treatment of thromboembolic disorders

Country Status (11)

Country Link
US (1) US20250099466A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401736A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024534427A (cg-RX-API-DMAC7.html)
KR (1) KR20240060820A (cg-RX-API-DMAC7.html)
AU (1) AU2022345862A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232633A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000776A1 (cg-RX-API-DMAC7.html)
IL (1) IL310894A (cg-RX-API-DMAC7.html)
MX (1) MX2024002857A (cg-RX-API-DMAC7.html)
TW (1) TW202327607A (cg-RX-API-DMAC7.html)
WO (1) WO2023043999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565231A1 (en) * 2022-08-01 2025-06-11 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke
CN121001727A (zh) * 2023-04-19 2025-11-21 百时美施贵宝公司 米尔维仙(milvexian)于治疗及预防患有心血管或脑血管疾病的患者的血栓病况的用途
CN121443289A (zh) * 2023-04-19 2026-01-30 百时美施贵宝公司 米尔维仙在治疗或预防患有急性冠状动脉综合征的患者的不良脑血管事件或不良心血管事件中的用途
CN121398811A (zh) * 2023-04-19 2026-01-23 百时美施贵宝公司 米尔维仙于治疗及预防患有心房颤动的患者的血栓病况的用途
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2026115567A1 (en) * 2024-11-26 2026-06-04 Dr. Reddy’S Laboratories Limited Sustained release formulations of milvexian

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR20210151183A (ko) 2019-04-11 2021-12-13 브리스톨-마이어스 스큅 컴퍼니 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능

Also Published As

Publication number Publication date
US20250099466A1 (en) 2025-03-27
JP2024534427A (ja) 2024-09-20
KR20240060820A (ko) 2024-05-08
TW202327607A (zh) 2023-07-16
CA3232633A1 (en) 2023-03-23
CL2024000776A1 (es) 2024-07-26
AU2022345862A1 (en) 2024-03-14
MX2024002857A (es) 2024-03-21
WO2023043999A1 (en) 2023-03-23
EP4401736A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
JP2024534427A5 (cg-RX-API-DMAC7.html)
Shetty et al. A prospective randomized study to analyze the efficacy of balanced pre-emptive analgesia in spine surgery
US20080139667A1 (en) Pharmaceutical Compositions For the Treatment of Disease and/or Symptoms in Arthritis
KR100516676B1 (ko) 안면 수술에서의 레보부피바카인의 용도
JP2017510607A5 (cg-RX-API-DMAC7.html)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
KR20160080111A (ko) 경추 및 요추 질환 치료용 약물
US9545419B1 (en) Method and compositions for treating chronic inflammatory disorders
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
WO2025137652A3 (en) Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders
KR102927058B1 (ko) 진통 가려움 완화 약학 조성물 및 그 응용 방법
US6194460B1 (en) Composition for treating cough induced by angiotensin converting enzyme inhibitors
Sharma et al. Comparative study of preclosure periportal instillation of three different concentrations of ropivacaine (0.125%, 0.25%, 0.5%) for postoperative analgesia in laparoscopic cholecystectomy
Beute (Oral) enoximone in asthma
Sharma et al. Efficacy and Safety of Transdermal versus Intravenous Diclofenac for Postoperative Analgesia in Pediatric Inguinal Surgeries: A Comparative Study
CN107468917B (zh) 一种化痰解毒治疗冠心病的中药组合物及其应用
WO2000050028A1 (en) Compositions for the treatment of pain
CN1682715A (zh) 一种抗缺氧药物组合物
CN121550202A (zh) 索法酮作为trpv3抑制剂在制备治疗皮肤疾病药物中的应用
CN113786433A (zh) 一种用于骨性疾病疼痛的药物组方
WO2026107041A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain
CN120605308A (zh) 珍宝丸在制备用于预防脑卒中的药物中的应用